Department of oncology, First People Hospital of Lianyungang, Lianyungang, Jiangsu province, 222002, China.
Cell Oncol (Dordr). 2012 Jun;35(3):175-80. doi: 10.1007/s13402-012-0075-7. Epub 2012 Apr 3.
To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC).
Three hundred twenty patients with Stage III (A+B) or IV NSCLC were enrolled. A Platinum-based chemotherapy was given to each subjects and therapeutic effect was evaluated. The two galectin-3 genetic polymorphisms, namely, galectin-3 +191 A>C and +292 A>C, were genotyped.
The polymorphic genotypes and the allele frequency of galectin-3 +191 A>C were not significantly different between responders and non-responders to chemotherapy. For galectin-3 +292 A>C, the AA genotype and A allele distribution were significantly higher in responders than in non-responders. Logistic regression analysis showed CC genotype of galectin-3 +292 presented higher risk of being non-responders compared with the AA genotype (OR = 2.96, 95 % CI: 1.55-5.47; P < 0.001). The overall survival in patients with AA genotype of galectin-3 +292 were significantly longer than in those with CC genotype (25.6 vs. 19.5 months, P = 0.013). The hazard ratio for CC genotype of galectin-3 +292 was 2.43 (95 % CI: 2.03-3.98, compared with AA carriers, P = 0.003).
The galectin-3 genetic polymorphisms of galectin-3 +292, rather than galectin-3 +191, were associated with the chemotherapy response and prognosis of NSCLC.
探讨半乳糖凝集素-3（Galectin-3）基因多态性与铂类化疗反应及非小细胞肺癌（NSCLC）预后的关系。
纳入 320 例 III（A+B）期或 IV 期 NSCLC 患者。每位患者均接受铂类化疗，并评估治疗效果。对 Galectin-3 的两个基因多态性，即 Galectin-3 +191 A>C 和 +292 A>C，进行基因分型。
Galectin-3 +191 A>C 的多态基因型和等位基因频率在化疗反应者和非反应者之间无显著差异。Galectin-3 +292 A>C 中，AA 基因型和 A 等位基因在化疗反应者中的分布显著高于非反应者。Logistic 回归分析显示，Galectin-3 +292 的 CC 基因型与 AA 基因型相比，发生非反应的风险更高（OR=2.96，95%CI：1.55-5.47；P<0.001）。Galectin-3 +292 中 AA 基因型的患者总生存时间明显长于 CC 基因型（25.6 个月 vs. 19.5 个月，P=0.013）。Galectin-3 +292 的 CC 基因型的危险比为 2.43（95%CI：2.03-3.98，与 AA 携带者相比，P=0.003）。
Galectin-3 +292 而非 Galectin-3 +191 的基因多态性与 NSCLC 的化疗反应和预后相关。
